Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

141. Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. Full Text available with Trip Pro

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. Here we examine the relationship between achieving different levels of disease activity with tofacitinib (an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis), long-term structural progression, and patient-reported physical function.This was a post hoc analysis of two 24-month, phase III randomized controlled trials

2018 Rheumatology and therapy Controlled trial quality: uncertain

142. Tofacitinib (rheumatoid arthritis) - Addendum to Commission A17-18

Tofacitinib (rheumatoid arthritis) - Addendum to Commission A17-18 1 Translation of addendum A17-43 Tofacitinib (rheumatoide Arthritis) – Addendum zum Auftrag A17-18 (Version 1.0; Status: 28 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 28 September 2017 1.0 Commission: A17-43 Version: Status: IQWiG Reports – Commission No. A17-43 (...) Tofacitinib (rheumatoid arthritis) – Addendum to Commission A17-18 1 Addendum A17-43 Version 1.0 Tofacitinib – Addendum to Commission A17-18 28 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Tofacitinib (rheumatoid arthritis) – Addendum to Commission A17-18 Commissioning agency: Federal Joint Committee Commission awarded on: 4 September 2017 Internal Commission No.: A17-43 Address

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

143. Rheumatoid arthritis

Rheumatoid arthritis Rheumatoid arthritis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Rheumatoid arthritis Last reviewed: February 2019 Last updated: September 2018 Summary A chronic, erosive arthritis that requires early and aggressive treatment. Diagnosed clinically. Laboratory and radiographic testing provide prognostic information more often than diagnostic information. Methotrexate is the anchor drug (...) for the treatment of RA. Disease activity scores (e.g., 28-joint count version of disease activity score [DAS28], clinical disease activity index [CDAI], simplified disease activity index [SDAI], routine assessment patient index data [RAPID3]) are used routinely to provide optimum care for RA patients. Definition Rheumatoid arthritis (RA) is a chronic inflammatory condition affecting around 1% of the population, making it the most common inflammatory arthritis seen by physicians. Lee DM, Weinblatt ME

2018 BMJ Best Practice

144. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial Full Text available with Trip Pro

Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial To explore whether tocilizumab + tapering MTX has comparable efficacy and safety vs tocilizumab + stable MTX in adult RA patients with inadequate response to MTX.This randomized, placebo-controlled non-inferiority study involved patients with severe active RA [28-joint DAS (DAS28) >5.1] who had initiated tocilizumab + MTX at the study start. Patients received open

2018 EvidenceUpdates

145. Physical Activity to Reduce Fatigue in Rheumatoid Arthritis: A Randomized Controlled Trial Full Text available with Trip Pro

Physical Activity to Reduce Fatigue in Rheumatoid Arthritis: A Randomized Controlled Trial Effective treatments for rheumatoid arthritis (RA) fatigue are limited. We tested the effect of a pedometer-based intervention on increasing physical activity and decreasing fatigue among individuals with RA.Participants completed baseline questionnaires; had 1 week of activity monitoring; were randomized to control (education [EDUC]), pedometer and step-monitoring diary (PED), or pedometer and diary plus

2018 EvidenceUpdates

146. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies Full Text available with Trip Pro

Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies To evaluate the progression of erosions and joint space narrowing (JSN) in feet and hands in the U-Act-Early trial.In this trial, 317 newly diagnosed DMARD-naïve RA patients initiated randomly tocilizumab, or step-up MTX or a combination of the two. Radiographs were scored at baseline and after 52 and 104 weeks using the Sharp-van der Heijde erosion and JSN

2018 EvidenceUpdates

147. Effectiveness of an overall progressive resistance strength program for improving the functional capacity of patients with rheumatoid arthritis: a randomized controlled trial (Abstract)

Effectiveness of an overall progressive resistance strength program for improving the functional capacity of patients with rheumatoid arthritis: a randomized controlled trial To evaluate the effectiveness of overall progressive resistance training in patients with rheumatoid arthritis.Randomized controlled clinical trial with blinded assessor and intention-to-treat analysis.Outpatient clinics.Sixty patients with rheumatoid arthritis according to the American College of Rheumatology criteria

2018 EvidenceUpdates

148. Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Extract 1 Translation of the executive summary of the dossier assessment Tofacitinib (Rheumatoide Arthritis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. IQWiG Reports – Commission No. A18-28 Tofacitinib (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A18-28 Version 1.0 Tofacitinib (rheumatoid arthritis) 27 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Tofacitinib (rheumatoid arthritis) – Benefit assessment according

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

149. Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and Crohn's disease

Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and Crohn's disease '); } else { document.write(' '); } ACE | Infliximab for the treatment of rheumatoid arthritis ankylosing spondylitis psoriatic arthritis plaque psoriasis ulcerative colitis and crohns disease Search > > Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis (...) and Crohn's disease - Infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and Crohn's disease Published on 1 March 2018 Guidance Recommendation The Ministry of Health’s Drug Advisory Committee has recommended: Infliximab biosimilar (Remsima) 100mg vial for the treatment of: Adults with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, ulcerative

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

150. Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity Full Text available with Trip Pro

Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity Serum cartilage oligomeric matrix protein (COMP) is a non-collagen glycoprotein produced by the cartilage, synovium, tendon, and meniscus. Recent studies showed that COMP is a reliable factor for monitoring cartilage damage.To determine the relationship between serum COMP concentration and the severity of rheumatoid arthritis (RA).This cross-sectional study lasted from 2013 to 2015

2017 Electronic physician

151. Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis Full Text available with Trip Pro

Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis Sarilumab is a human monoclonal antibody that blocks the interleukin-6 receptor alpha (IL-6Rα). The phase 3 SARIL-RA-EASY study (EASY) assessed the robustness of an autoinjector (pen) for administering sarilumab when used by adults with active moderate-to-severe rheumatoid arthritis (RA) who are candidates for anti-IL-6R therapy in an unsupervised real-world

2017 Rheumatology and therapy Controlled trial quality: uncertain

152. A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States Full Text available with Trip Pro

A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States Understanding the effects of corticosteroid utilization prior to initiation of biologic disease-modifying antirheumatic drugs (DMARDs) can inform decision-makers on the appropriate use of these medications. This study examined treatment patterns and associated burden of corticosteroid utilization before initiation of biologic DMARDs among (...) rheumatoid arthritis (RA) patients.A retrospective analysis was conducted of adult RA patients in the US MarketScan Database (2011-2015). The following patterns of corticosteroid utilization were analyzed: whether corticosteroids were used; duration of use (short/long duration defined as < or ≥ 3 months); and dosage (low as < 2.5, medium as 2.5 to < 7.5 and high as ≥ 7.5 mg/day). Effects of corticosteroid use on time to biologic DMARD initiation were examined using Cox proportional hazards models

2017 Rheumatology and therapy

153. Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis Full Text available with Trip Pro

Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis Essentials Can venous thromboembolism (VTE) in rheumatoid arthritis (RA) patients be marker of cancer? RA patients with VTE and comparison cohorts from population-based registries were compared. Increased risk of cancer in RA patients with VTE during the first year of VTE was observed. Risk of cancer in RA patients was increased also during the longer period following VTE.Background It is unknown whether venous (...) thromboembolism (VTE) in rheumatoid arthritis (RA) patients can be a marker of occult cancer. Objectives To examine risk of cancer subsequent to VTE among RA patients compared with risk of cancer in an RA cohort without VTE and in a general population without RA and without VTE. Patients/Methods All RA patients with a first-time diagnosis of VTE (index date) during 1978-2013 and comparison cohorts were identified from population-based registries in Denmark. Results We identified three cohorts: 2497 RA

2017 EvidenceUpdates

154. Sirukumab (Plivensia) - rheumatoid arthritis

Sirukumab (Plivensia) - rheumatoid arthritis 26 October 2017 Dr. Tomas Salmonson Chair of Committee for Medicinal Products for Human Use European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Subject: Withdrawal of Plivensia (sirukumab), 50 mg, solution for injection, pre-filled syringe and pre-filled pen - EMEA/H/C/004165/0000 Dear Dr. Salmonson We would like to inform you that, at this point of time, Janssen-Cilag International NV has taken the decision (...) to withdraw the application for Marketing Authorisation of Plivensia (sirukumab), 50 mg, solution for injection, pre-filled syringe and pre-filled pen, which was intended to be used for the treatment of moderately to severely active rheumatoid arthritis in adult patients. This withdrawal is based on the following reason: The Company made a global strategic decision to prioritize other assets in our portfolio, given the need for additional clinical data that would result in significant delays to patient

2017 European Medicines Agency - EPARs

155. Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.8 of the dossier assessment Baricitinib (Rheumatoide Arthritis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 June 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-14 (...) Baricitinib (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-14 Version 1.0 Baricitinib (rheumatoid arthritis) 29 June 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Baricitinib (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

156. Adalimumab (Cyltezo) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis

Adalimumab (Cyltezo) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Hidradenitis Suppurativa, Psoriasis, Ankylosing Spondylitis, Uveitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided (...) Control QTPP Quality Target Product Profile RA Rheumatoid arthritis RF Rheumatoid factor RH Relative Humidity RLCA Response Level Correlation Assay RPN Risk Priority Number RPP Reference Product Pool RT Room Temperature s.c. Subcutaneous SAF Safety analysis set SCB Safety Cell Bank SD Standard deviation SPR Surface Plasmon Resonance t1/2 Terminal half-life of the analyte in plasma TEM Transmission electron microscopy tmax Time from (last) dosing to the maximum measured concentration in plasma TNF

2017 European Medicines Agency - EPARs

157. Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study Full Text available with Trip Pro

Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study 'REASSURE' (NCT01377012), a phase 3 study, evaluated the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to, or intolerance of, tumor necrosis factor inhibitors (TNF-inhibitors).A total of 637 patients were randomized (1:1:1) to receive intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4

2017 Rheumatology and therapy Controlled trial quality: predicted high

158. Physical activity and sedentary behavior in patients with systemic lupus erythematosus and rheumatoid arthritis Full Text available with Trip Pro

Physical activity and sedentary behavior in patients with systemic lupus erythematosus and rheumatoid arthritis Patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). As sedentary behavior and lack of physical activity are known cardiovascular risk factors, we compared habitual activity between SLE patients, RA patients, and healthy control participants.For this cross-sectional study, RA and SLE patients were

2017 Open access rheumatology : research and reviews

159. Mortality in Italian patients with rheumatoid arthritis: evidence for a low mortality rate from cancer and infections in patients followed up at a tertiary center Full Text available with Trip Pro

Mortality in Italian patients with rheumatoid arthritis: evidence for a low mortality rate from cancer and infections in patients followed up at a tertiary center Mortality in patients with rheumatoid arthritis (RA) has never been investigated in Italy. This study is devoted to investigating all the distinct causes of mortality in Italian RA patients.Clinical charts of patients consecutively admitted to an Italian tertiary center, from January 1, 2008 to December 31, 2014, were reviewed (...) by the National Institute of Statistics was observed. All-cause and neoplasm IMRs in our series were found to be significantly lower than that reported in the Norfolk Arthritis Registry, while no difference was detected in cardiovascular (CV) mortality. On the other hand, all causes and CV SMRs in our series were found to be higher than that reported in the general Italian population, while cancer and infectious SMRs were found to be lower.In our series, RA patients had an increased all-cause mortality

2017 Open access rheumatology : research and reviews

160. Sarilumab for moderate to severe rheumatoid arthritis

Sarilumab for moderate to severe rheumatoid arthritis Sarilumab for moder Sarilumab for moderate to se ate to sev vere ere rheumatoid arthritis rheumatoid arthritis T echnology appraisal guidance Published: 1 November 2017 nice.org.uk/guidance/ta485 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sarilumab for moderate to severe rheumatoid arthritis (TA485) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 22Contents Contents 1 Recommendations 4 2 The technology 6 3 Committee discussion 7

2017 National Institute for Health and Clinical Excellence - Technology Appraisals